Video Experimental Relacionado
Updated: Jun 27, 2026
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
La aspirina altera los efectos cardioprotectores del polimorfismo del factor XIII Val34Leu, que tiene un efecto
Anetta Undas1, Wojciech J Sydor, Kathleen Brummel
1Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland.
Circulation
|January 8, 2003
Resumen
La aspirina inhibe más eficazmente la activación del factor XIII (FXIII) en individuos con el polimorfismo Leu34. Esta mayor inhibición sugiere que los portadores de Leu34 pueden obtener una mayor reducción del riesgo de infarto de miocardio con dosis bajas de aspirina.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacogenética La farmacogenética.
- La hemostasis y la trombosis
Sus antecedentes:
- El mecanismo cardioprotector del polimorfismo del factor (F) XIII Leu34 no se entiende completamente.
- El efecto de la aspirina sobre el fibrinógeno y la FXIII activada por la trombina sugiere una posible interacción con el polimorfismo de Val34Leu.
Objetivo del estudio:
- Investigar si la aspirina afecta diferencialmente la activación del factor XIII en individuos con el polimorfismo Val34Leu.
Principales métodos:
- Comparación de las tasas de activación de FXIII en portadores de Leu34 y homocigotos de Val34 antes y después de 7 días de tratamiento con aspirina (75 mg/día).
- Se utilizó el Western blotting cuantitativo en muestras de sangre secuenciales de sitios de lesiones microvasculares.
Principales resultados:
- El alelo Leu34 aumentó significativamente las tasas de activación FXIII mediadas por la trombina.
- La aspirina inhibió la activación de FXIII más profundamente en los portadores de Leu34 en comparación con los homocigotos de Val34.
- El efecto de la aspirina en la generación de trombina fue similar entre los dos grupos.
Conclusiones:
- La inhibición de la activación de FXIII por parte de la aspirina se mejora en los portadores de Leu34.
- Los portadores de Leu34 pueden experimentar una mayor reducción del riesgo de infarto de miocardio con el tratamiento con dosis bajas de aspirina.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...